CNBX Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CNBX Pharmaceuticals generated cash of -$244,269, which is less than the previous year. Cash used in financing activities reached the amount of $27,512 last year. Net change in cash is therefore -$103,280.
Cash Flow
| 2015 | -179.05K | -3.04K | 108.55K |
|---|---|---|---|
| 2016 | -120.10K | 0 | 114K |
| 2017 | -863.56K | -125.77K | 4.33M |
| 2018 | -1.97M | -1.44M | 1.44M |
| 2019 | -3.09M | -5.25M | 7.21M |
| 2020 | -2.77M | 3.28M | 0 |
| 2021 | -2.49M | 645.02K | 2.45M |
| 2022 | -1.67M | 25.22K | 389.85K |
| 2023 | -112.52K | 24.70K | 100K |
| 2024 | -244.26K | 113.47K | 27.51K |
CNBX Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 129.69K | 117.51K | 1.38M | 777.61K | 265.98K | 1.39M | 3.36M | 19.12K | 25.22K | 98.76K |
Operating activities | ||||||||||
Net income | -695.19K | -3.71M | -3.72M | -3.19M | -7.46M | 1.13M | -3.77M | -1.93M | -307.18K | -541.38K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 72.32K | 162.06K | 198.52K | 220.92K | 215.15K | 188.92K | 88.44K | 7.01K | 1.57K | 1.30K |
Stock-based compensation expense | 139.72K | 180.48K | 728.86K | 33.76K | 72.12K | 247.30K | 0 | 1.02M | 29.85K | 83.12K |
| Deferred income tax benefit | 139.72K | 180.48K | 728.86K | 33.76K | 72.12K | 247.30K | 0 | 1.02M | 29.85K | 83.12K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 89.64K | -13.84K | 123.60K | -10.41K | 132.19K | -57.25K | -77.56K | -146.71K | -2.69K | 13.71K |
Inventories | 0 | 0 | 0 | 53.63K | -15.91K | 0 | -1.08M | -2.81M | 469.07K | 0 |
Accounts payable | 43.51K | 487.96K | 283.62K | -53.63K | 15.91K | -100.50K | -71.13K | 121.54K | 149.05K | 88.50K |
Cash generated by operating activities | -244.26K | -112.52K | -1.67M | -2.49M | -2.77M | -3.09M | -1.97M | -863.56K | -120.10K | -179.05K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -5.03M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -1.65K | -943 | -75.74K | -216.88K | -942.39K | -125.77K | 0 | -3.04K |
Acquisitions Net | 0 | 0 | 26.88K | 0 | 0 | 5.25M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 113.47K | 24.70K | 25.22K | 645.02K | 3.28M | -5.25M | -1.44M | -125.77K | 0 | -3.04K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 7.29M | 1.55M | 4.41M | 94K | 108.55K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -85K | 0 | 0 | 0 |
Repayments of term debt | 0 | 100K | 389.85K | -2.45M | 0 | 0 | -22K | 21.41K | -20K | 0 |
Cash used in financing activities | 27.51K | 100K | 389.85K | 2.45M | 0 | 7.21M | 1.44M | 4.33M | 114K | 108.55K |
Net Change In Cash | -103.28K | 12.18K | -1.26M | 608.86K | 511.62K | -1.12M | -1.97M | 3.34M | -6.10K | -73.53K |
Cash at end of period | 26.41K | 129.69K | 117.51K | 1.38M | 777.61K | 265.98K | 1.39M | 3.36M | 19.12K | 25.22K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |